Cancer and Leukemia Group B - The Ohio State University

描述（由申请人提供）：本补助金的目的是通过为俄亥俄州州立大学（OSU）的CALGB计划提供必要的基础设施，支持癌症和白血病组B（CALGB）的科学和临床活动。俄勒冈州立大学的多学科合作研究方法在提供预防，检测和治疗成人癌症的更有效方法方面有着良好的记录，特别关注乳腺癌，胃肠道癌，泌尿生殖系统癌，血液学和呼吸系统恶性肿瘤。这项研究集中了医学，血液学，外科和放射肿瘤学家，移植师，精神病学家，病理学家，细胞遗传学家，翻译和基础实验室科学家，统计学家，流行病学家，护士，药剂师，和临床研究协调员，精心设计和开展研究，提出相互关联的临床和基础科学问题，这些问题的答案对患者护理和减少人群癌症有重要贡献风险更大该项目包括：1）在I、II和III期临床试验中研究新的治疗剂及其毒性; 2）评估新方案的功效和毒性，包括新和旧药剂的组合，以努力更有效地利用协同组合; 3）开发针对特定肿瘤问题的多模式方法，以最佳组合使用手术、免疫学和放射学措施; 4）在特定治疗方案的设计和执行中涉及相关的基础科学学科，如分子遗传学、生物化学、药理学、免疫学和生物统计学; 5）通过使用这些协议来教育博士生和博士后学生、护士、专职医疗人员和医生，改善社区的癌症护理，6）评估与临床终点相关的生物学研究，以制定更合理的癌症管理，7）评估癌症控制工作，如早期检测，以及8）研究癌症的心理社会方面。在Clara D.布卢姆菲尔德，医学博士，俄勒冈州立大学通过患者参与方案，制定和领导研究方案，领导和参与CALGB的科学和行政委员会，多个CALGB核心实验室和设施的住房，CALGB会议参与和集团出版物的作者身份，为CALGB活动做出贡献。此外，俄勒冈州立大学进行机构试点，并提供实验室数据，导致新的CALGB研究。对这一计划的支持将提高我们预防、检测、治疗和治愈成人癌症的能力，并提高癌症幸存者的生活质量。

DESCRIPTION (provided by applicant): The purpose of this grant is to support the scientific and clinical activities of Cancer and Leukemia Group B (CALGB) by providing necessary infrastructure to the CALGB program at The Ohio State University (OSU). The multi-disciplinary collaborative research approach at OSU has a track record of providing more effective methods of prevention, detection and treatment of adult cancer, with a particular focus on breast, gastrointestinal, genitourinary, hematologic, and respiratory malignancies. This research focuses the efforts of medical, hematologic, surgical and radiation oncologists, transplanters, psychiatrists, pathologists, cytogeneticists, translational and basic laboratory scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research coordinators on well designed and conducted studies asking interrelated clinical and basic science questions whose answers contribute importantly to patient care and to reduction of cancer in populations at increased risk. This project includes the: 1) study of new therapeutic agents, and their toxicities, in Phase I, II and III clinical trials; 2) evaluation of efficacy and toxicity of new regimens including combinations of new and old agents in an effort to exploit synergistic combinations more effectively; 3) development of multi-modal approaches to specific tumor problems using surgical, immunological and radiotherapeutic measures in optimal combinations; 4) involvement of pertinent basic science disciplines such as molecular genetics, biochemistry, pharmacology, immunology, and biostatistics in the design and execution of specific therapy protocols; 5) improvement of cancer care in the community by using these protocols to educate pre- and post-doctoral students, nurses, allied medical personnel and physicians, 6) evaluation of biologic studies in correlation with clinical endpoints to develop more rationally based cancer management, 7) evaluation of cancer controls efforts such as early detection, and 8) study of the psycho-social aspects of cancer. Under the overall coordination of Clara D. Bloomfield, M.D., OSU contributes to CALGB activities through patient accrual to protocols, development and leadership of research protocols, leadership and participation in the scientific and administrative committees of CALGB, housing of multiple CALGB core labs and facilities, CALGB meeting participation and authorship on Group publications. In addition, OSU performs institutional pilots and provides lab data that lead to new CALGB studies. Support of this program should increase our ability to prevent, detect, treat and cure adult cancer and improve the quality of life of cancer survivors.